Are decreased AdipoR1 mRNA levels associated with adiponectin resistance in coronary artery disease patients?
Authorized Users Only
Article (Published version)
MetadataShow full item record
The aim of the present study was to investigate if circulating adiponectin levels and the expression of AdipoR1 and AdipoR2 in peripheral blood mononuclear cells (PBMC) are altered in coronary artery disease (CAD) patients, with and without significant stenosis, compared to healthy patients. The present study included 69 patients with presenting symptoms of CAD (26 patients with significant stenosis and 43 patients without significant stenosis). The control group (CG) consisted of 33 healthy patients. Circulating adiponectin levels were measured by enzyme-linked immunosorbent assay, whereas AdipoR1 and AdipoR2 mRNA levels in PBMC were determined by real-time polymerase chain reaction. Adiponectin levels were significantly higher in patients with and without significant stenosis compared to the CG (P lt 0.001 vs P=0.006, respectively). Both patient groups had lower AdipoR1 levels compared to the CG (P lt 0.001 vs P lt 0.001, respectively). There were no significant differences in these ...parameters between the two patient groups. Adiponectin negatively correlated with body mass index, triglycerides, insulin and homeostasis model assessment of insulin resistance index (HOMA IR), and positively with high-denisty lipoprotein cholesterol in the CG. Glucose, insulin, and the HOMA IR index negatively correlated with adiponectin in patients. A positive correlation between adiponectin receptors was found in patients and the CG. Decreased AdipoR1 mRNA levels and increased circulating adiponectin in advanced stages of CAD, as well as in patients without significant stenosis, compared to the CG, implies that CAD could be related to adiponectin resistance'. Despite increased adiponectin, its protective effects could be diminished even in early stages of atherosclerosis.
Keywords:adiponectin / AdipoR1 mRNA / AdipoR2 mRNA / coronary artery disease
Source:Clinical and Experimental Pharmacology and Physiology, 2015, 42, 4, 331-336
- Wiley, Hoboken